Refractory Acute Lymphoblastic Leukemia Recruiting Phase 1 / 2 Trials for Cyclophosphamide (DB00531)

Also known as: Acute Lymphoblastic Leukemia, Refractory / Acute, refractory Lymphoblastic Leukemia / Acute, refractory Lymphocytic leukaemia / Acute, refractory Lymphocytic Leukemia / Acute lymphocytic leukemia refractory / Acute, refractory Lymphoblastic Leukaemia / Acute lymphocytic leukaemia refractory / Refractory Acute lymphoblastic leukaemia

IndicationStatusPhase
DBCOND0058624 (Refractory Acute Lymphoblastic Leukemia)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03573700Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic LeukemiaTreatment
NCT03670966211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeTreatment